TG Therapeutics, Inc. (NASDAQ:TGTX) Files An 8-K Submission of Matters to a Vote of Security Holders

TG Therapeutics, Inc. (NASDAQ:TGTX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.Submission of Matters to a Vote of Security Holders.

TG Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders on Wednesday, June 13, 2018 at the offices of its legal counsel, Alston & Bird LLP, 90 Park Avenue, New York, New York 10016 at 9:30 a.m. Eastern Standard Time. Stockholders representing 62,395,470, or 80.33%, of the 77,666,112 shares entitled to vote were present in person or by proxy. Proxies were solicited by the Company to Regulation 14A under the Securities Exchange Act of 1934, as amended. At the annual meeting, Proposals 1, 2, and 3 were approved. The proposals below are described in detail in the Company’s definitive proxy statement dated April 30, 2018 for the annual meeting.

The results are as follows:

Proposal 1

The following persons were nominated and elected directors:

Michael S.

Weiss

Laurence N.

Charney

William J.

Kennedy

Mark

Schoenebaum, MD

Yann

Echelard

Kenneth

Hoberman

Daniel

Hume

The shareholder voting for board members is summarized as follows:

Director

Votes For

Votes Withheld

Abstentions

Broker Non-Votes

Michael S. Weiss

34,700,747

4,776,720

0

22,918,003

Laurence N. Charney

25,138,011

14,339,456

0

22,918,003

William J. Kennedy

25,139,461

14,338,006

0

22,918,003

Mark Schoenebaum, MD

22,987,997

16,489,470

0

22,918,003

Yann Echelard

32,433,930

7,043,537

0

22,918,003

Kenneth Hoberman

32,420,553

7,056,914

0

22,918,003

Daniel Hume

32,433,698

7,043,769

0

22,918,003

All seven directors will serve on the board of directors of the Company (the “Board”) until the 2019 annual meeting.

Proposal 2

CohnReznick LLP was approved as the Company’s independent registered public accountant for the fiscal year ending December 31, 2018.

The votes cast were as follows:

Votes For

Votes Against

Abstentions

Broker Non-Votes

61,581,162

365,659

448,649

0

Proposal 3

The amendment to the Amended and Restated 2012 Incentive Plan (the “Plan”) was approved to increase the number of shares of common stock available for issuance under the Plan by 6,000,000.

The votes cast were as follows:

Votes For

Votes Against

Abstentions

Broker Non-Votes

33,670,966

5,283,744

522,757

22,918,003


About TG Therapeutics, Inc. (NASDAQ:TGTX)

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.

An ad to help with our costs